DaVita (DVA)
(Delayed Data from NYSE)
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$137.72 USD
+1.77 (1.30%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Thermo Fisher (TMO) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the third quarter, Thermo Fisher (TMO) invests more than $140 million to increase the production of its laboratory plastic consumables.
3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings
by Sriparna Ghosal
These three MedTech stocks are expected to grow post their Q3 earnings release.
Aphria (APHA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.
Here's Why You Should Add AngioDynamics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.
Will Walgreens (WBA) Post Dull Retail Numbers in Q4 Earnings?
by Zacks Equity Research
Walgreens' (WBA) retail pharmacy international sales remain dull in Q4 on difficult market scenario in the U.K.
Veeva Develops 2 Applications on Veeva Clinical Network (Revised)
by Zacks Equity Research
This should boost Veeva's (VEEV) portfolio of cloud-based offerings for the life sciences industry.
Should Value Investors Buy DaVita HealthCare (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pacific Biosciences Unveils Sequel IIe for HiFi Sequencing
by Zacks Equity Research
Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology.
Ecolab Disinfectant Gets EPA Nod for Use Against SARS-CoV-2
by Zacks Equity Research
Ecolab's (ECL) Peroxide Multi Surface Cleaner and Disinfectant is the first EPA-registered disinfectant proven to be effective at killing the SARS-CoV-2 virus.
Ecolab Launches Sanitizer to Prevent Food-Borne Illness
by Zacks Equity Research
Ecolab's (ECL) Sink & Surface Cleaner Sanitizer is the first EPA-registered product for use against norovirus and SARS-CoV-2.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
New Strong Buy Stocks for October 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Zacks.com featured highlights include: Whirlpool, TEGNA, DaVita, General Motors and Berry Global
by Zacks Equity Research
Zacks.com featured highlights include: Whirlpool, TEGNA, DaVita, General Motors and Berry Global
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
5 PEG-Focused Value Picks to Shield From Market Meltdown
by Urmimala Biswas
This apparently simple-to-understand investing discipline has its own share of pitfalls.
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
DaVita (DVA): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
DaVita (DVA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Zacks.com featured highlights include: DVA, LEN, PCAR and MAS
by Zacks Equity Research
Zacks.com featured highlights include: DVA, LEN, PCAR and MAS
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Buy Stocks For September 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
NOA, CNXN, DVA and EXLS as Zacks Bull and Bear of the Day
by Zacks Equity Research
NOA, CNXN, DVA and EXLS as Zacks Bull and Bear of the Day
4 GARP Picks to Shield Your Portfolio From September Meltdown
by Urmimala Biswas
Market sentiment is down lately due to Fed's muted outlook and rising cases of coronavirus in Europe.
What's Driving Estimates on New Strong Buy Stocks?
by Sejuti Banerjea
Amid all the uncertainty and negativity, the clear sign that we are getting into more favorable territory is the increase in earnings estimates. Here is a quick look at what is driving some of the numbers.
New Strong Buy Stocks For September 21st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: